CoChat

The Dexamethasone-Suppressed Corticotropin-Releasing Hormone Test for the Diagnosis of Cushing’s Syndrome: What Have We Learned in 14 Years?

Nieman, Lynnette · 2007 · The Journal of Clinical Endocrinology & Metabolism
Cited by 24

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Although Cushing’s syndrome is uncommon, many of its characteristics are common in the general population, including obesity, depression, hypertension, and reproductive abnormalities, raising the question of who should be screened for the disorder. Elevated urine free cortisol (up to 4-fold over normal levels) also may be present in patients with psychiatric disease, obesity, alcohol abuse, and pain. Recently the term “pseudo-Cushing’s” has been used to identify such individuals with mild clinical and/or biochemical features of Cushing’s syndrome (1). Because urine free cortisol cannot establish pathological hypercortisolism unless it is quite elevated, there is a need for additional tests to confirm the diagnosis of Cushing’s syndrome. The dexamethasone suppression test (DST) takes advantage of the fact that Cushing’s syndrome patients with primary adrenal disease or ectopic ACTH-secreting tumors do not respond to dexamethasone, whereas those with corticotrope adenomas generally show some suppression of cortisol, albeit less than normal individuals. The 1-mg DST (administration of dexamethasone between 2300 and 0000 h, with measurement of serum cortisol the next morning) has a high false positive rate but relatively high sensitivity (2). The 2-mg or low-dose DST (LDDST) (administration of 500 μg dexamethasone every 6 h with measurement of serum cortisol 2 or 6 h after the last dose) has high sensitivity and specificity (3). The utility of dexamethasone suppression is limited in individuals with altered metabolism of dexamethasone because of hepatic or renal disease or in those who take medications that alter CYP3A4 activity and dexamethasone clearance (4). Elevated corticosteroid-binding globulin (CBG) also can give a false positive result. Demonstration of a normal serum cortisol at midnight can exclude Cushing’s syndrome but is impractical (5). Measurement of late-night salivary free cortisol is more convenient, but there is considerable assay variability and no single diagnostic threshold has been validated (6, 7).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2007-1289

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 6

  1. Luo, 2004, CYP3A4 induction by xenobiotics: Biochemistry, experimental methods and impact on drug discovery and development., Curr Drug Metab, 5, 483, 10.2174/1389200043335397 · DOI
  2. Papanicolaou, 1998, A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing states., J Clin Endocrinol Metab, 83, 1163
  3. Yanovski, 1998, The dexamethasone-suppressed corticotropin-releasing hormone stimulation test differentiates mild Cushing’s disease from normal physiology., J Clin Endocrinol Metab, 83, 348
  4. Erickson, 2007, Dexamethasone-suppressed corticotropin-releasing hormone stimulation test for diagnosis of mild hypercortisolism., J Clin Endocrinol Metab, 92, 2973, 10.1210/jc.2006-2662 · DOI · Paper page
  5. Martin, 2006, Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing’s syndrome., J Clin Endocrinol Metab, 91, 2582, 10.1210/jc.2005-2143 · DOI · Paper page
  6. Aron, 1997, Effectiveness versus efficacy: The limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome., J Clin Endocrinol Metab, 82, 1780

Cited by

Metadata

Authors
Nieman, L.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2007-08-01
Volume
92
Issue
8
Pages
2876-2878
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2057265251
Cited by
24
References
7
FWCI
1.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.